ADMA — ADMA Biologics Balance Sheet
0.000.00%
Last trade - 00:00
- $1.45bn
- $1.53bn
- $258.22m
- 74
- 11
- 97
- 64
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 26.8 | 55.9 | 51.1 | 86.5 | 51.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3.47 | 13.2 | 28.6 | 15.5 | 27.4 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 85.8 | 154 | 209 | 270 | 257 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 33.1 | 45.9 | 58.2 | 68.7 | 63.5 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 127 | 208 | 276 | 348 | 329 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 14 | 19.9 | 30.4 | 39.3 | 49.8 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 101 | 119 | 135 | 196 | 194 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 26.2 | 88.2 | 141 | 152 | 135 |
Total Liabilities & Shareholders' Equity | 127 | 208 | 276 | 348 | 329 |
Total Common Shares Outstanding |